Targeting mutations predictably

Schreiber, Hans; Rowley, Janet D.; Rowley, Donald A.

doi:10.1182/blood-2011-06-357541

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progresses in “omics” will enable linking genetic alterations with the type of immune response. Novel protocols will be tailored to the patient-specific mutation (Schreiber et al, 2011) and immune alterations the patients display. Thus, there has never been a more exciting time for working on cancer vaccines.…”

Section: Discussionmentioning

confidence: 99%

Dendritic-Cell-Based Therapeutic Cancer Vaccines

2013

View full text Add to dashboard Cite

The past decade has seen tremendous developments in novel cancer therapies, through targeting of tumor cell-intrinsic pathways whose activity is linked to genetic alterations, as well as the targeting of tumor cell-extrinsic factors such as growth factors. Furthermore, immunotherapies are entering the clinic at an unprecedented speed following the demonstration that T cells can efficiently reject tumors and that their anti-tumor activity can be enhanced with antibodies against immune regulatory molecules (checkpoints blockade). Current immunotherapy strategies include monoclonal antibodies against tumor cells or immune regulatory molecules, cell-based therapies such as adoptive transfer of ex vivo activated T cells and natural killer (NK) cells, and cancer vaccines. Herein, we discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of dendritic cell (DC) and T cell biology might enable development of next-generation curative therapies for patients with cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Dendritic-Cell-Based Therapeutic Cancer Vaccines

2013

View full text Add to dashboard Cite

show abstract

“…So far however, even clinically effective drugs are not truly cancer-specific; for example, imatinib inhibits the normal Abelson kinase not just the BCR-ABL fusion protein. 18 Therefore, no current approach targets cancer cells or their stromal microenvironment 19 in a truly cancer-specific way.…”

Section: Role Of Microenvironmentmentioning

confidence: 99%

Epidemiology and biology of relapse after stem cell transplantation

Horowitz

Schreiber

Elder

et al. 2018

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

Michálek

Héžová

Turanek-Knotigova

et al. 2016

Cancer Immunol Immunother

View full text Add to dashboard Cite

The natural adjuvant properties of bacterial ghosts (BGs) lie within the presence of intact pathogen-associated molecular patterns on their surface. BGs can improve the direct delivery, natural processing and presentation of target antigens within dendritic cells (DCs). Moreover, sensitization of human DCs by cancer cell lysate (oncolysate)-loaded BGs in the presence of IFN-α and GM-CSF enhanced DC maturation as indicated by an increased expression of maturation markers and co-stimulatory molecules, higher production of IL-12p70 and stimulation of significantly increased proliferation of both autologous CD4 and CD8 T cells compared to DCs matured in the presence of purified lipopolysaccharide. The induced T cells efficiently recognized oncolysate-derived tumor-associated antigens expressed by cancer cells used for the production of oncolysate. Our optimized one-step simultaneous antigen delivery and DC maturation-inducing method emerges as a promising tool for the development and implementation of next-generation cellular cancer immunotherapies.

show abstract

Targeting mutations predictably

Cited by 5 publications

References 8 publications

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Epidemiology and biology of relapse after stem cell transplantation

Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

Contact Info

Product

Resources

About